

- a VL region having the following CDRs:
    - LC-CDR1 having the amino acid sequence of SEQ ID NO:90
    - LC-CDR2 having the amino acid sequence of SEQ ID NO:92
    - LC-CDR3 having the amino acid sequence of SEQ ID NO:96; or
  - (d)
    - a VH region having the following CDRs:
      - HC-CDR1 having the amino acid sequence of SEQ ID NO:41
      - HC-CDR2 having the amino acid sequence of SEQ ID NO:45
      - HC-CDR3 having the amino acid sequence of SEQ ID NO:47; and
    - a VL region having the following CDRs:
      - LC-CDR1 having the amino acid sequence of SEQ ID NO:88
      - LC-CDR2 having the amino acid sequence of SEQ ID NO:93
      - LC-CDR3 having the amino acid sequence of SEQ ID NO:95; or
  - (e)
    - a VH region having the following CDRs:
      - HC-CDR1 having the amino acid sequence of SEQ ID NO:41
      - HC-CDR2 having the amino acid sequence of SEQ ID NO:45
      - HC-CDR3 having the amino acid sequence of SEQ ID NO:49; and
    - a VL region having the following CDRs:
      - LC-CDR1 having the amino acid sequence of SEQ ID NO:88
      - LC-CDR2 having the amino acid sequence of SEQ ID NO:93
      - LC-CDR3 having the amino acid sequence of SEQ ID NO:95; or
  - (f)
    - a VH region having the following CDRs:
      - HC-CDR1 having the amino acid sequence of SEQ ID NO:41
      - HC-CDR2 having the amino acid sequence of SEQ ID NO:45
      - HC-CDR3 having the amino acid sequence of SEQ ID NO:50; and
    - a VL region having the following CDRs:
      - LC-CDR1 having the amino acid sequence of SEQ ID NO:88
      - LC-CDR2 having the amino acid sequence of SEQ ID NO:93
      - LC-CDR3 having the amino acid sequence of SEQ ID NO:95; or
  - (g)
    - a VH region having the following CDRs:
      - HC-CDR1 having the amino acid sequence of SEQ ID NO:41
      - HC-CDR2 having the amino acid sequence of SEQ ID NO:45
      - HC-CDR3 having the amino acid sequence of SEQ ID NO:48; and
    - a VL region having the following CDRs:
      - LC-CDR1 having the amino acid sequence of SEQ ID NO:88
  - LC-CDR2 having the amino acid sequence of SEQ ID NO:92
  - LC-CDR3 having the amino acid sequence of SEQ ID NO:95; or
  - (h)
    - a VH region having the following CDRs:
      - HC-CDR1 having the amino acid sequence of SEQ ID NO:41
      - HC-CDR2 having the amino acid sequence of SEQ ID NO:45
      - HC-CDR3 having the amino acid sequence of SEQ ID NO:48; and
    - a VL region having the following CDRs:
      - LC-CDR1 having the amino acid sequence of SEQ ID NO:88
      - LC-CDR2 having the amino acid sequence of SEQ ID NO:92
      - LC-CDR3 having the amino acid sequence of SEQ ID NO:97; or
  - (i)
    - a VH region having the following CDRs:
      - HC-CDR1 having the amino acid sequence of SEQ ID NO:42
      - HC-CDR2 having the amino acid sequence of SEQ ID NO:45
      - HC-CDR3 having the amino acid sequence of SEQ ID NO:48; and
    - a VL region having the following CDRs:
      - LC-CDR1 having the amino acid sequence of SEQ ID NO:88
      - LC-CDR2 having the amino acid sequence of SEQ ID NO:92
      - LC-CDR3 having the amino acid sequence of SEQ ID NO:95; or
  - (j)
    - a VH region having the following CDRs:
      - HC-CDR1 having the amino acid sequence of SEQ ID NO:41
      - HC-CDR2 having the amino acid sequence of SEQ ID NO:44
      - HC-CDR3 having the amino acid sequence of SEQ ID NO:47; and
    - a VL region having the following CDRs:
      - LC-CDR1 having the amino acid sequence of SEQ ID NO:88
      - LC-CDR2 having the amino acid sequence of SEQ ID NO:92
      - LC-CDR3 having the amino acid sequence of SEQ ID NO:98.
- 27.** The antigen-binding molecule according to claim **24**, wherein the antigen-binding molecule comprises:
- (a) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:24; and a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:74; or
  - (b) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:25; and a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:75; or